-
Je něco špatně v tomto záznamu ?
CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria
DR. Sutherland, SJ. Richards, F. Ortiz, R. Nayyar, M. Benko, I. Marinov, A. Illingworth
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2002
Medline Complete (EBSCOhost)
od 2012-03-01 do Před 1 rokem
Wiley Free Content
od 2003 do Před 1 rokem
PubMed
31705743
DOI
10.1002/cyto.b.21853
Knihovny.cz E-zdroje
- MeSH
- antigeny CD59 metabolismus MeSH
- buněčná diferenciace MeSH
- CD antigeny krev fyziologie MeSH
- diferenciální diagnóza MeSH
- erytrocyty metabolismus patologie MeSH
- glykoforin metabolismus MeSH
- imunofenotypizace přístrojové vybavení metody normy MeSH
- kohortové studie MeSH
- leukocyty patologie MeSH
- lidé MeSH
- monocyty metabolismus patologie MeSH
- neutrofily metabolismus patologie MeSH
- paroxysmální hemoglobinurie krev klasifikace diagnóza patologie MeSH
- počet leukocytů přístrojové vybavení metody MeSH
- průtoková cytometrie přístrojové vybavení metody normy MeSH
- receptory transferinu krev fyziologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on flow cytometric demonstration of loss of glycosyl-phosphatidyl inositol (GPI)-anchored proteins from red blood cells (RBC) and white blood cells (WBC). High-sensitivity multiparameter assays have been developed to detect loss of GPI-linked structures on PNH neutrophils and monocytes. High-sensitivity assays to detect PNH phenotypes in RBCs have also been developed that rely on the loss of GPI-linked CD59 on CD235a-gated mature RBCs. The latter is used to delineate PNH Type III (total loss of CD59) and PNH Type II RBCs (partial loss of CD59) from normal (Type I) RBCs. However, it is often very difficult to delineate these subsets, especially in patients with large PNH clones who continue to receive RBC transfusions, even while on eculizumab therapy. METHODS: We have added allophycocyanin (APC)-conjugated CD71 to the existing CD235aFITC/CD59PE RBC assay allowing simultaneous delineation and quantification of PNH Type III and Type II immature RBCs (iRBCs). RESULTS: We analyzed 24 medium to large-clone PNH samples (>10% PNH WBC clone size) for PNH Neutrophil, PNH Monocyte, Type III and Type II PNH iRBCs, and where possible, Type III and Type II PNH RBCs. The ability to delineate PNH Type III, Type II, and Type I iRBCs was more objective compared to that in mature RBCs. Additionally, total PNH iRBC clone sizes were very similar to PNH WBC clone sizes. CONCLUSIONS: Addition of CD71 significantly improves the ability to analyze PNH clone sizes in the RBC lineage, regardless of patient hemolytic and/or transfusion status.
Cytoquest Corporation Toronto Ontario Canada
Dahl Chase Diagnostic Services Bangor Maine
EXBIO Praha a s Vestec Czech Republic
HMDS St James University Hospital Leeds UK and Experimental Haematology University of Leeds UK
Institute of Hematology and Blood Transfusion Prague Czech Republic
Laboratory Medicine Program Toronto General Hospital Toronto Ontario Canada
Sprott Centre for Stem Cell Research Ottawa Hospital Research Institute Toronto Ontario Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020705
- 003
- CZ-PrNML
- 005
- 20250611091542.0
- 007
- ta
- 008
- 210728s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/cyto.b.21853 $2 doi
- 035 __
- $a (PubMed)31705743
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sutherland, D Robert $u Laboratory Medicine Program, Toronto General Hospital, Toronto, Ontario, Canada
- 245 10
- $a CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria / $c DR. Sutherland, SJ. Richards, F. Ortiz, R. Nayyar, M. Benko, I. Marinov, A. Illingworth
- 520 9_
- $a BACKGROUND: The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on flow cytometric demonstration of loss of glycosyl-phosphatidyl inositol (GPI)-anchored proteins from red blood cells (RBC) and white blood cells (WBC). High-sensitivity multiparameter assays have been developed to detect loss of GPI-linked structures on PNH neutrophils and monocytes. High-sensitivity assays to detect PNH phenotypes in RBCs have also been developed that rely on the loss of GPI-linked CD59 on CD235a-gated mature RBCs. The latter is used to delineate PNH Type III (total loss of CD59) and PNH Type II RBCs (partial loss of CD59) from normal (Type I) RBCs. However, it is often very difficult to delineate these subsets, especially in patients with large PNH clones who continue to receive RBC transfusions, even while on eculizumab therapy. METHODS: We have added allophycocyanin (APC)-conjugated CD71 to the existing CD235aFITC/CD59PE RBC assay allowing simultaneous delineation and quantification of PNH Type III and Type II immature RBCs (iRBCs). RESULTS: We analyzed 24 medium to large-clone PNH samples (>10% PNH WBC clone size) for PNH Neutrophil, PNH Monocyte, Type III and Type II PNH iRBCs, and where possible, Type III and Type II PNH RBCs. The ability to delineate PNH Type III, Type II, and Type I iRBCs was more objective compared to that in mature RBCs. Additionally, total PNH iRBC clone sizes were very similar to PNH WBC clone sizes. CONCLUSIONS: Addition of CD71 significantly improves the ability to analyze PNH clone sizes in the RBC lineage, regardless of patient hemolytic and/or transfusion status.
- 650 _2
- $a CD antigeny $x krev $x fyziologie $7 D015703
- 650 _2
- $a antigeny CD59 $x metabolismus $7 D018957
- 650 _2
- $a buněčná diferenciace $7 D002454
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a erytrocyty $x metabolismus $x patologie $7 D004912
- 650 _2
- $a průtoková cytometrie $x přístrojové vybavení $x metody $x normy $7 D005434
- 650 _2
- $a glykoforin $x metabolismus $7 D006021
- 650 _2
- $a paroxysmální hemoglobinurie $x krev $x klasifikace $x diagnóza $x patologie $7 D006457
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunofenotypizace $x přístrojové vybavení $x metody $x normy $7 D016130
- 650 _2
- $a počet leukocytů $x přístrojové vybavení $x metody $7 D007958
- 650 _2
- $a leukocyty $x patologie $7 D007962
- 650 _2
- $a monocyty $x metabolismus $x patologie $7 D009000
- 650 _2
- $a neutrofily $x metabolismus $x patologie $7 D009504
- 650 _2
- $a receptory transferinu $x krev $x fyziologie $7 D011990
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Richards, Stephen J $u HMDS, St James University Hospital, Leeds, UK & Experimental Haematology, University of Leeds, UK
- 700 1_
- $a Ortiz, Fernando $u Sprott Centre for Stem Cell Research, Ottawa Hospital Research Institute, Toronto, Ontario, Canada
- 700 1_
- $a Nayyar, Rakesh $u Cytoquest Corporation, Toronto, Ontario, Canada
- 700 1_
- $a Benko, M. $u EXBIO, Praha, a.s. Vestec, Czech Republic $7 xx0332972
- 700 1_
- $a Marinov, Iuri $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
- 700 1_
- $a Illingworth, Andrea $u Dahl-Chase Diagnostic Services, Bangor, Maine
- 773 0_
- $w MED00013936 $t Cytometry. Part B, Clinical cytometry $x 1552-4957 $g Roč. 98, č. 2 (2020), s. 179-192
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31705743 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20250611091534 $b ABA008
- 999 __
- $a ok $b bmc $g 1691310 $s 1141151
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 98 $c 2 $d 179-192 $e 20191108 $i 1552-4957 $m Cytometry. Part B, Clinical cytometry $n Cytometry B Clin Cytom $x MED00013936
- LZP __
- $a Pubmed-20210728
